Olvidé mi contraseña
Asóciese a SIIC en Internet para utilizar sin límites tanto siicsalud como la totalidad de los servicios bibliográficos de la institución.
¿Cuál es la complicación crónica más frecuente de esta patología?
Introducción:
La diabetes mellitus es una enfermedad metabólica crónica que se asocia con la aparición de diversas complicaciones, fundamentalmente a raíz de alteraciones microvasculares y macrovasculares.
Lectura recomendada:
Preventive Pharmacotherapy in Type 2 Diabetes Mellitus
Indian Journal of Endocrinology and Metabolism, 16(1):33-43
Lectura recomendada:
Effects of a Home-Based Walking Intervention on Mobility and Quality of Life in People With Diabetes and Peropheral Arterial Disease
Diabetes Care, 34(10):2174-2179
Lectura recomendada:
Postprandial Blood Glucose Predicts Cardiovascular Events and All-Cause Mortality in Type 2 Diabetes in a 14-Year Follow-Up
Diabetes Care, 34(10):2237-2243
Lectura recomendada:
Intensive Glycemic Control Has no Impact on the Risk of Heart Failure in Type 2 Diabetic Patients: Evidence From a 37,229 Patient Meta-Analysis
American Heart Journal, 162(5):938-948
Lectura recomendada:
High-Intensity Aerobic Training Improves Endothelium-Dependent Vasodilation in Patients With Metabolic Syndrome and Type 2 Diabetes Mellitus
Diabetes Research and Clinical Practice, 95(2):237-245
Lectura recomendada:
Saxagliptin: A Review of Its Use as a Combination Therapy in the Management of Type 2 Diabetes Mellitus in the EU
Drugs, 72(2):229-248
¿Cuál de estos mecanismos de acción se propone para la repaglinida en los pacientes con diabetes tipo 2?
Introducción:
La diabetes es una enfermedad de proporciones epidémicas en todo el mundo. Esta afección se vincula con repercusiones importantes para la salud pública. El mecanismo patogénico fundamental es la disfunción de las células beta del páncreas, con deficiencia de insulina, resistencia a esta hormona en los tejidos periféricos y alteraciones en la secreción de otras hormonas.
Lectura recomendada:
Repaglinide: A Review of Its Use in Type 2 Diabetes Mellitus
Drugs, 72(2):249-272
Lectura recomendada:
Pharmacologic Prevention of Microvascular and Macrovascular Complications in Diabetes Mellitus: Implications of the Results of Recent Clinical Trials in Type 2 Diabetes
American Journal of Cardiovascular Drugs, 12(1):7-22
Lectura recomendada:
Time Trends in Absolute and Modifiable Coronary Heart Disease Risk in Patients With Type 2 Diabetes in the Swedish National Diabetes Register (NDR) 2003-2008
Diabetic Medicine, 29(2):198-206
Lectura recomendada:
Increased Prevalence of Chronic Kidney Diseases in Patients With Type 1 Diabetes and Non Alcoholic Fatty Liver
Diabetic Medicine, 29(2):220-226
Lectura recomendada:
Glycemic Control and Cardiovascular Mortality in Hemodialysis Patients With Diabetes: A 6-Year Cohort Study
Diabetes, 61(3):708-715
Lectura recomendada:
Evaluation of the Effects of Glimepiride (Amaryl) and Repaglinide (novoNorm) on Atherosclerosis Progression in High Cholesterol-Fed Male Rabbits
Journal of Cardiovascular Disease Research, 3(1):5-11
Lectura recomendada:
Relationship Between A1C and Fasting Plasma Glucose in Dysglycemia or Type 2 Diabetes: An Analysis of Baseline Data From the ORIGIN Trial
Diabetes Care,
Lectura recomendada:
Impact of Introducing HbA1c Into the Diagnostic Criteria on Prevalence and Cardiovascular Risk Profiles of Individuals With Newly Diagnosed Diabetes in Japan: The Toranomon Hospital Health Management Center Study 2 (Topics 2)
Diabetes Research and Clinical Practice, 95(2):283-290
Lectura recomendada:
Racial/Ethnic- and Education-Related Disparities in the Control of Risk Factors for Cardiovascular Disease Among Individuals With Diabetes
Diabetes Care, 35(2):305-312
Lectura recomendada:
Nonalcoholic Fatty Liver Disease is Associated With Left Ventricular Diastolic Dysfunction in Patients With Type 2 Diabetes
Diabetes Care, 35(2):389-395
Lectura recomendada:
Strategies to Detect Abnormal Glucose Metabolism in People at High Risk of Cardiovascular Disease From the ORIGIN (Outcome Reduction With Initial Giargine Intervention) Trial Population
Journal of Diabetes, 3(3):232-237